Objectif FLUTCORE will develop a novel universal influenza A virus (IAV) vaccine based on the tandem core vaccine platform. Recent influenza pandemics have emphasized the urgent need for better vaccines that are reactive with multiple IAV subtypes and that are no longer dependent on intimate knowledge of the prevalent virus. We propose to replace the existing seasonal IAV vaccine with a virus like particle (VLP) carrying several invariant “universal” influenza antigens. Previous attempts to use these targets have failed due to the poor antigen expression and immunogenicity. The highly immunogenic tandem core system overcomes this limitation.Specifically, we propose to develop a VLP carrying two or more invariant influenza antigens, express these in yeast and then examine immunogenicity in mice. The vaccine will be further tested in the rigorous ferret system before being scaled up for manufacture. An optimal clone will then be transferred to an accredited contract manufacturer for production. A phase I clinical trial will be carried out once pre-clinical toxicology has been successfully completed. Our consortium will examine the immune responses in both animals and humans thoroughly to ensure that the vaccine candidate chosen can produce a protective IAV immune response in all individuals.To achieve these objectives, our proposal builds upon the complementary expertise of seven high-performing partners representing four European countries, with world leadership in HBV core biology, immunological analysis, commercial manufacture and influenza clinical trials, making our consortium ideally positioned to develop the vaccine and to take it from bench to bedside. The leading role of SMEs in the consortium will ensure that the technology developed by FLUTCORE will generate highly marketable products, offering both improved patient protection and long-term cost savings for health care in Europe once annual influenza vaccines are replaced. Champ scientifique natural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis Bmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.3.0-1 - Innovation in vaccines Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur UNIVERSITY COLLEGE LONDON Contribution de l’UE € 657 202,44 Adresse GOWER STREET WC1E 6BT London Royaume-Uni Voir sur la carte Région London Inner London — West Camden and City of London Type d’activité Higher or Secondary Education Establishments Contact administratif Michael Browne (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (6) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire UNIVERSITY OF LEEDS Royaume-Uni Contribution de l’UE € 269 606,89 Adresse WOODHOUSE LANE LS2 9JT Leeds Voir sur la carte Région Yorkshire and the Humber West Yorkshire Leeds Type d’activité Higher or Secondary Education Establishments Contact administratif Martin Hamilton (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS Lettonie Contribution de l’UE € 315 657,27 Adresse RATSUPITES IELA 1 1067 Riga Voir sur la carte Région Latvija Latvija Rīga Type d’activité Research Organisations Contact administratif Liga Vonda Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée IQUR LIMITED Royaume-Uni Contribution de l’UE € 945 758,25 Adresse ROYAL COLLEGE STREET 2 LONDON NW1 0NH LONDON Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Mike Whelan (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée LUXEMBOURG INSTITUTE OF HEALTH Luxembourg Contribution de l’UE € 666 407,59 Adresse 1A RUE RUE THOMAS EDISON 1445 Strassen Voir sur la carte Région Luxembourg Luxembourg Luxembourg Type d’activité Research Organisations Contact administratif Thomas Lentz (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée 3P BIOPHARMACEUTICALS SL Espagne Contribution de l’UE € 289 082,77 Adresse CALLE MOCHOLI 2 POLIGONO MOCHOLI 31110 NOAIN NAVARRA Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Barbara Fernandez De Manzanos (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée INSTITUT CATALA DE LA SALUT Espagne Contribution de l’UE € 18 588,45 Adresse GRAN VIA DE LES CORTS CATALANES 587 08007 Barcelona Voir sur la carte Région Este Cataluña Barcelona Type d’activité Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contact administratif Joan X. Comella (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée